LAMIVUDINE, NEVIRAPINE AND ZIDOVUDINE Drug Patent Profile
✉ Email this page to a colleague
When do Lamivudine, Nevirapine And Zidovudine patents expire, and when can generic versions of Lamivudine, Nevirapine And Zidovudine launch?
Lamivudine, Nevirapine And Zidovudine is a drug marketed by Micro Labs and is included in one NDA.
The generic ingredient in LAMIVUDINE, NEVIRAPINE AND ZIDOVUDINE is lamivudine; nevirapine; zidovudine. There are twenty-nine drug master file entries for this compound. Additional details are available on the lamivudine; nevirapine; zidovudine profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for LAMIVUDINE, NEVIRAPINE AND ZIDOVUDINE?
- What are the global sales for LAMIVUDINE, NEVIRAPINE AND ZIDOVUDINE?
- What is Average Wholesale Price for LAMIVUDINE, NEVIRAPINE AND ZIDOVUDINE?
Summary for LAMIVUDINE, NEVIRAPINE AND ZIDOVUDINE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Clinical Trials: | 45 |
| DailyMed Link: | LAMIVUDINE, NEVIRAPINE AND ZIDOVUDINE at DailyMed |
Recent Clinical Trials for LAMIVUDINE, NEVIRAPINE AND ZIDOVUDINE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Johns Hopkins University | Phase 1/Phase 2 |
| The Aurum Institute NPC | Phase 1/Phase 2 |
| French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS) | Phase 4 |
See all LAMIVUDINE, NEVIRAPINE AND ZIDOVUDINE clinical trials
US Patents and Regulatory Information for LAMIVUDINE, NEVIRAPINE AND ZIDOVUDINE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Micro Labs | LAMIVUDINE, NEVIRAPINE AND ZIDOVUDINE | lamivudine; nevirapine; zidovudine | TABLET;ORAL | 205626-001 | Aug 13, 2018 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
